13F Holdings
中文EN

HROW HARROW, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1360214 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY21.3%
TTM net income YoY-471.2%
TTM EPS YoY-484.6%
Revenue 3-yr CAGR38.5%
Net income 3-yr CAGR—

Margins

Gross margin73.5%
Operating margin-2.0%
Net margin-9.4%
FCF margin-6.7%
EBITDA margin-1.4%

Returns

ROE-74.8%
ROA-7.1%
ROIC (approx.)-3.5%
Asset turnover0.75x

Leverage & solvency

Liabilities / assets93.5%
Debt / equity0.00x
Current ratio2.29x
Interest coverage-0.26x

Cash quality & payout

Operating cash flow / net income0.67x
Accruals ratio-2.4%
Payout ratio—
Capex / revenue0.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$272.30M$199.61M$130.19M$88.59M$72.48M
Cost of revenue$67.93M$49.24M$39.64M$25.38M$18.21M
Gross profit$204.37M$150.37M$90.55M$63.21M$54.26M
R&D expense$20.94M$12.23M$6.65M$3.05M$11.08M
SG&A expense$152.91M$129.06M$83.09M$58.24M$41.31M
Operating income$30.52M$8.82M$431,000$1.92M$1.61M
Interest expense$24.18M$22.79M$21.32M$7.24M$5.44M
Pretax income-$1.37M-$17.32M-$23.71M-$14.01M-$17.87M
Income tax$3.77M$161,000$701,000$75,000$133,000
Net income-$5.14M-$17.48M-$24.41M-$14.09M-$18.01M
EBITDA$32.43M$10.67M$1.96M$3.40M$3.33M
EPS (basic)-0.14-0.49-0.75-0.51-0.69
EPS (diluted)-0.14-0.49-0.75-0.51-0.69
Weighted avg. shares (diluted)36.76M35.65M32.62M27.46M26.76M
Banking
Net interest income————-$5.44M
Balance sheet
Cash & equivalents$72.93M$47.25M$74.08M$96.27M$42.17M
Short-term investments——$8.68M$5.59M$8.50M
Receivables$110.89M$116.37M$36.26M$6.25M$4.47M
Inventory$13.52M$10.70M$10.87M$6.54M$4.22M
Current assets$211.75M$189.65M$139.48M$118.26M$60.66M
PP&E, net$3.26M$3.73M$3.52M$3.49M$3.14M
Goodwill$332,000$332,000$332,000$332,000$332,000
Intangibles$175.17M$184.95M$159.91M$23.73M$15.81M
Total assets$399.48M$388.97M$312.16M$157.38M$98.33M
Current liabilities$96.30M$91.34M$49.34M$18.63M$9.72M
Long-term debt$250.00M$262.74M$246.72M$151.77M$103.03M
Total debt$250.00M$262.74M$246.72M$151.77M$103.03M
Total liabilities$347.39M$319.67M$241.75M$130.14M$87.40M
Shareholders' equity$52.45M$69.65M$70.77M$27.59M$11.29M
Net debt$177.07M$215.49M$172.63M$55.50M$60.87M
Shares outstanding37.23M35.62M35.17M29.90M26.90M
Cash flow statement
Operating cash flow$43.86M-$22.20M$3.84M$1.71M$5.08M
Capital expenditure$887,000$1.59M$1.46M$2.60M$1.79M
Free cash flow$42.98M-$23.80M$2.38M-$892,000$3.30M
Investing cash flow-$5.46M-$33.16M-$152.55M-$1.74M-$18.69M
Financing cash flow-$12.72M$28.53M$126.53M$54.14M$51.47M
Depreciation & amortization$1.92M$1.85M$1.53M$1.48M$1.72M
Stock-based compensation$12.50M$17.62M$15.70M$7.97M$5.75M

Free plan shows the latest 5 periods; Pro shows all 27 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.